Innovation and night light in large and small cities. by Saul Estrin (8629173)

Differences in mean number of papers (top) and co-authors (bottom) depending on (1) NI membership and (2) time joined NI. by William C. Barley (8915282)

Subjects:

Regression estimates and incidence rate ratios from GLMER for number of papers (top) and coauthors (bottom). by William C. Barley (8915282)

Subjects:

Summary map of all contacts with statistically significant SVM classifications. by Alexander P. Rockhill (6053618)

“…<p>The top row presents the proportion of significant SVM clusters. It illustrates what proportions of channels are significant at that time-frequency ranging from 0 to 1. …”

Negative ion mode significant differential metabolites (Fold Change greater than 2 or less than 0.5). by Peng-fei Han (694841)

Positive ion mode significant differential metabolites (Fold Change greater than 2 or less than 0.5). by Peng-fei Han (694841)

Introgression decreases allelic shuffling. by Enrique J. Schwarzkopf (6579275)

Why does task performance decrease with burst length? by Swathi Anil (17382903)

Flow chart of participants selection. by Linjia Duan (13276989)

Subjects:

Sobel test for the significance of the mediation effect. by Getachew Magnar Kitila (19935139)

Sensitivity to small changes. by Ariel Burman (20329776)

Madrasin decreases transcription of protein-coding genes. by Michael Tellier (8284752)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

The spike-in of synthetic hsa-lest-7a-5p miRNA decreases the Ct Values of extracted small RNA samples. by Marc Van Der Hofstadt (1423027)

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects:

Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

Subjects:

Study-related adverse events. by Benjamin R. Lewis (22279166)

Subjects: